<DOC>
	<DOC>NCT01099124</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and tolerance of M2ES with TC regimen in advanced NSCLC.</brief_summary>
	<brief_title>Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>1. Aged 1870 years old; 2. Patients with Ⅲ/Ⅳ NSCLC confirmed by histopathology or cytology who ware naive or previous chemotherapy without TC regimen; 3. No contraindication for chemotherapy; 4. ECOG performance scale 02; 5. No history of antiangiogenesis therapy; 6. Patients are voluntary to participate and sigh the informed contents. 1. Concurrent use of other anticancer agents; 2. Allergic history to M2ES and biological agents; 3. Pregnant or breastfeeding women; 4. With other malignancy; 5. With severe cardiopulmonary disease; 6. Uncontrolled brain metastasis patients; 7. Other conditions that are regarded for exclusion by the trialists.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>M2ES</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Phase I Trial</keyword>
	<keyword>Advanced NSCLC</keyword>
	<keyword>Recurrent NSCLC</keyword>
</DOC>